While marketed clot busters address one of the primary components of stroke - the thrombus - no treatments are available for ischemia-induced brain damage, the other main component of stroke. Researchers at The Scripps Research Institute last week published in Nature Medicine the use of a Src kinase inhibitor that protected ischemic mice from brain damage, thereby opening up a new mechanism by which this second component may be addressed.